An initial public offering for Bristol-Myers Squibb's subsidiary, Mead Johnson Nutrition, will initialize the week of Feb. 9 at a price of $21 to $24 per share of Class A common stock, which will trade under the ticker symbol MJN. Net proceeds are estimated at $530 million to $610 million, depending on whether underwriters exercise over-allotment actions, according to a prospectus filed Jan. 28. Based on the implied IPO price, the marketer of Enfamil pediatric formula likely will have 200 million shares and a market value of $4.5 billion, according to Deutsche Bank analyst Barbara Ryan. BMS intends to maintain an 80 percent to 90 percent ownership stake in Mead Johnson, which generated $2.88 billion in net sales in 2008. In April 2008, BMS announced plans to spin off the nutritionals business in an IPO rather than sell it (1"The Tan Sheet," April 28, 2008, p. 14)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
EU authorities must “take advantage” of the upcoming Biotech Act to reassess the bloc’s policies and “offset existing challenges” for small and midsized enterprises, trade association EUCOPE has said.
The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get your submissions in by this date. Sponsorship opportunities and tables for the event are also available.